Market Research Reports

Hospital Acquired Disease Testing Market (Pneumonia, UTI, Blood Stream, Surgical Site, MRSA Infection, and Others) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023

85pages
Published Date: 2015-12-24

Description


This report covers the market analysis for various diagnostic tests performed to detect hospital associated infections, also called as nosocomial infections. Morbidity rate of nosocomial infections is increasing rapidly worldwide, thereby driving the hospital associated infection (HAI) diagnostic market towards remarkable growth. The stakeholders for this study include manufacturers and providers of diagnostic solutions for nosocomial infections. 

The global hospital acquired disease testing market is categorized on the basis of test types, i.e., urinary tract infection, surgical site infection, pneumonia, blood stream infection, MRSA infection, and others. A detailed market analysis and forecast for these segments has been provided in this study, in terms of market revenue (US$ Mn) for the period 2013 to 2023. The report also provides with the compounded annual growth rate (CAGR %) for each infection type for the forecast period 2015 to 2023, while market size estimations have been made considering 2014 as the base year. 

In terms of geographical distribution, the global hospital acquired disease testing market has been classified into four geographical areas: North America, Europe, Asia Pacific, Latin America and the Middle East & Africa. The current and future market sizes (in terms of US$ Mn) of the above regional markets have been provided in the report for the period 2013 to 2023 with their growth rate (%) for the period 2015 to 2023. The study further offers recommendations and highlights of the market, which would be useful for the current and future market players to sustain and grow in the global hospital acquired disease testing market. 

The market overview section of the report demonstrates the market dynamics and market trends such as the drivers, restraints and opportunities that influence the current nature and future status of this field. Impact factors such as market attractiveness analysis and Porter’s five forces analysis have also been explained in the market overview section of the report, in order to give a thorough analysis of the overall competitive scenario in the global hospital acquired disease testing market.

 This report concludes with the company profiles section which includes key information about the major players in this market. Some of the key players profiled in this report include Diatherix Laboratories Inc., Gen-Probe Inc., Qiagen GmbH, L Hoffman La Roche, Cepheid, Inc., Life Technologies Corporation, Meridian Biosciences, Cantel Medical Corporation, Nordion, Inc. and others. 

The global hospital acquired disease testing market is segmented as follows: 

Global Hospital Acquired Disease Testing Market, by Test

  • Pneumonia infection
  • Urinary tract infection
  • Blood stream associated infection
  • Surgical site infection
  • MRSA infection
  • Others

Global Hospital Acquired Disease Testing Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Rest pf APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • Saudi Arabia
    • Rest of MEA

Table of Contents



Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology

Chapter 2 Executive Summary
2.1 Global Hospital Acquired Disease Testing Market Share, by Geography, 2014–2023 (US$ Mn)
2.2 Global Hospital Acquired Disease Testing Market, by Test, 2014 (US$ Mn)
2.3 Hospital Acquired Disease Testing Market Snapshot

Chapter 3 Hospital Acquired Disease Testing Market – Industry Analysis
3.1 Introduction
3.2 Market Drivers
     3.2.1 Establishment of government guidelines and code for prevention of HAIs
     3.2.2 Increase in prevalence of HAIs and rise in the number of drug resistant pathogens
3.3 Restraints
     3.3.1 Stringent regulations and guidance framework
     3.3.2 Lack of controlling authorities and control programs in less developed regions
3.4 Opportunity
     3.4.1 Passage of the Patient Care and Affordable Care Act in the U.S.
     3.4.2 Technological development in the field of molecular diagnostics
3.5 Porter’s Five Forces Analysis
3.6 Market Attractiveness Analysis– Hospital Acquired Disease Testing Market, by Geography (2014) (Value %) 

Chapter 4 Market Segmentation – By Test
4.1 Introduction
4.2 Global Hospital Acquired Disease Testing Market Revenue, by Test, 2013–2023 (US$ Mn)
     4.2.1 Global Urinary Tract Infection Testing Market Revenue, 2013–2023 (US$ Mn)
     4.2.2 Global Surgical Site Infection Testing Market Revenue, 2013–2023 (US$ Mn)
     4.2.3 Global Pneumonia Infection Testing Market Revenue, 2013–2023 (US$ Mn)
     4.2.4 Global Bloodstream Infection Testing Market Revenue, 2013–2023 (US$ Mn)
     4.2.5 Global Others Infection Testing Market Revenue, 2013–2023 (US$ Mn)

Chapter 5 Market Segmentation – By Geography
5.1 Introduction
5.2 Global Hospital Acquired Disease Testing Market Revenue, by Geography, 2013–2023 (US$ Mn)
5.3 North America Hospital Acquired Disease Testing Market Revenue, by Country, 2013–2023 (US$ Mn)
5.4 North America Hospital Acquired Disease Testing Market Revenue, by Test, 2013–2023 (US$ Mn)
5.5 Europe Hospital Acquired Disease Testing Market Revenue, by Country, 2013–2023 (US$ Mn)
5.6 Europe Hospital Acquired Disease Testing Market Revenue, by Test, 2013–2023 (US$ Mn)
5.7 Asia Pacific Hospital Acquired Disease Testing Market Revenue, by Country, 2013–2023 (US$ Mn)
5.8 Asia Pacific Hospital Acquired Disease Testing Market Revenue, by Test, 2013–2023 (US$ Mn)
5.9 Latin America Hospital Acquired Disease Testing Market Revenue, by Country, 2013–2023 (US$ Mn)
5.10 Latin America Hospital Acquired Disease Testing Market Revenue, by Test, 2013–2023 (US$ Mn)
5.11 Middle East & Africa Hospital Acquired Disease Testing Market Revenue, by Country, 2013–2023 (US$ Mn)
5.12 Middle East & Africa Hospital Acquired Disease Testing Market Revenue, by Test, 2013–2023 (US$ Mn)

Chapter 6 Recommendations

Chapter 7 Company Profiles
7.1 Abbott Laboratories
7.2 Alere, Inc. 
7.3 Becton, Dickinson and Company
7.4 bioMérieux SA
7.5 F. Hoffmann-La Roche Ltd.
7.6 Hologic, Inc.
7.7 QIAGEN
7.8 Siemens Healthcare
7.9 Diatherix Laboratories, Inc.
7.10 Meridian Bioscience, Inc.
7.11 Thermo Fisher Scientific, Inc. (Life Technologies Corporation)
7.12 Cepheid, Inc.

 

Free Market Analysis


Nosocomial infections, most commonly called as hospital acquired diseases or health care associated infections (HAI), are acquired by patients during their stay in hospitals. Since the last decade, remarkable prevalence of nosocomial infectionshas been observed worldwide and its morbidity rate is growing rapidly. Patients with weak immune system, those exposed to improper hygiene conditions in hospitals, the high neonatal population in developing countries and elderly patients across the globe are highly susceptible to nosocomial infections. Aging of population is one of the major factors that has increased the incidence rate of hospital acquired diseases worldwide. Growing morbidity rate has resulted in a rise in nosocomial infection mortality. 

Contraction of nosocomial infection prolongs hospital stay of patients and ultimately results in the increase in expenditure of patients. Though various diagnostic tests are available in the market for detection of infectious microorganisms, approximately 70% of such pathogens are becoming resistant to at least one of the anti-bacterial drugs most commonly used in nosocomial infection treatments, thus creating a challenge for health care professionals to treat such patients. Increasing resistance to commonly used antibiotics has created a demand for microorganism specific detection test for better assessment by healthcare professionals in order to provide appropriate treatment. Molecular diagnostics, PCR, microarrays and solid phase hybridization are some of the major techniques used for the diagnosis of nosocomial infections. The development of nucleic acid testing (NAT) diagnostic products and related platforms have enabled the entry of many players in the hospital acquired disease testing market.

Nosocomial infections are mainly categorized into six types depending on the kind of infection, namely, hospital acquired pneumonia, urinary tract infection, blood stream infection, surgical site infection, MRSA (Methicillin-resistant Staphylococcus aureus) infection and other miscellaneous variants which include gastro intestinal infection, cardiovascular infections, respiratory infections and infections related to joints. Occurrence of hospital acquired UTI is highest in all types of nosocomial infections, leading to the highest market share by revenue of hospital acquired UTI testing segment in the overall hospital acquired disease testing market. 

In order to reduce the incidence rate of hospital acquired infections and the cost burden related to the same, governments in developed countries are increasingly trying to control and prevent the spread of nosocomial infections through several in-house and inspective initiatives. Developed countries in North America, Australia and Europe have governmental organizations that focus on control and prevention of hospital acquired diseases in the respective country, e.g. the Centers for Disease Control and Prevention (CDC) in the United States and National Health and Medical Research Council in Australia. These authorities have set a framework of rules and recommendations for healthcare organizations to manage each type of nosocomial infection.  Recommendations framed by these institutions give detailed description of which test is to be performed for the diagnosis of which type of infection. Various methods such as blood culture tests, quantitative PCR, latex agglutination test, wound culture and tissue biopsy are commonly performed for nosocomial infection diagnosis. Newer diagnostic tools have enabled reduced turnaround time and accurate diagnosis of the infection, driving the hospital acquired disease testing market toward growth. 

Geographically, North America dominates the global hospital acquired disease testing market and is followed by Europe. Government initiatives to control and prevent nosocomial infection in these regions and their rigorous implementation to reduce the disease morbidity rate is driving the growth of nosocomial infection testing market. Asia Pacific is a lucrative market for hospital acquired disease testing owing to increased incidence of hospital acquired disease testing in countries like China and India and the growing need to reduce healthcare expenditure by both, the healthcare institutions and patients equally. Contribution by the Asian countries to the hospital acquired disease testing market is expected to increase further as the medical tourism industry flourishes in this region. 

hospital-acquired-disease-testing

 


To get discount on this report, just click on the button below.

To receive brochure, please click on the button below.

Report tailored as you need

If you feel this report needs customization, feel free to contact us. Our team of expert analyst can fulfil your requirements.

CUSTOMIZE REPORT

Upcoming Report

Payment
Copyright @ Transparency Market Research